Oxford UKR: Second decade outcome study

  • Research type

    Research Study

  • Full title

    Oxford Unicompartmental Knee Replacement: Second decade outcome study.

  • IRAS ID

    147767

  • Contact name

    David Murray

  • Contact email

    david.murray@ndorms.ox.ac.uk

  • Sponsor organisation

    Oxford University Hospitals NHS Trust

  • Duration of Study in the UK

    4 years, 11 months, 30 days

  • Research summary

    Unicompartmental knee replacement (UKR) is used for the treatment of painful osteoarthritis (OA) affecting one side of the knee joint. These knees can be treated by UKR rather than a total knee replacement (TKR), provided the other parts of the knee joint are in good condition. Traditionally UKR, such as the Phase 1 and Phase 2 Oxford knee, were implanted with incisions 20 cm long. In 1998 the Phase 3 Oxford knee was introduced using a minimally invasive (MIS) approach and an incision of 10cm. This MIS allowed patients to recover more quickly with fewer complications but there is concern that there may be a higher failure rate.

    There are no long term results of the Phase 3 MIS UKR and with the passage of time any implant is at a higher risk of failure so it is important to establish the success rate for MIS UKR in the second decade following implantation.

    The disadvantage of UKR is that the revision rate tends to be higher. The commonest mechanism of failure has been reported as lateral compartment osteoarthritis (LCOA). We need to determine the factors related to the progression of arthritis into the other compartments and identify the contributing factors then we may be able to prevent it. The only way to assess the incidence of LCOA is to see these patients, examine their knees and take an x-ray.

    This study aims to identify:
    - From post–operative x-rays, which patients are more at risk of developing Lateral Compartment Osteoarthritis in the second decade after surgery
    - The clinical outcome, at 10, 15 and 20 years following UKR
    - The radiological outcome including the incidence of progression of OA at 10, 15 and 20 years following MIS UKR, the factors predisposing to this and determine how progression of OA affects the clinical outcome.

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    15/SC/0324

  • Date of REC Opinion

    21 Jul 2015

  • REC opinion

    Further Information Favourable Opinion